Streptococcus pneumoniae is an important global pathogen that causes a wide range of
clinical disease in children and adults. Pneumococcal pneumonia is by far the common …

Patients with haematological malignancies are at high risk of infection because of various
mechanisms of humoral and cell-mediated immune deficiencies, which mainly depend on …

Background Changes in invasive pneumococcal disease (IPD) incidence were evaluated
after 7 years of 7-valent pneumococcal conjugate vaccine (PCV7) use in US children …

ContextAs the epidemiology of infections with methicillin-resistant Staphylococcus aureus
(MRSA) changes, accurate information on the scope and magnitude of MRSA infections in …

Background. The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) at the
population level is unclear. We explored PCV13's effect in reducing invasive pneumococcal …

Background Following universal recommendation for use of 13-valent pneumococcal
conjugate vaccine (PCV13) in US adults aged≥ 65 years in September 2014, we conducted …

Background Incidence, manifestations and case-fatality rate (CFR) of invasive
pneumococcal disease (IPD) vary with age and comorbidities. New vaccines, changing age …

Streptococcus pneumoniae is the most common cause of community-acquired pneumonia,
meningitis, and bacteremia in children and adults. Invasive pneumococcal disease (IPD) …

Background Immunosuppressed patients are at risk of severe viral infections-related
complications. National and international vaccination guidelines have been developed to …

Background: Pneumococcal disease remains a public health priority in adults. Safety and
immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine …